Arjun Gokulan M

Dr. Arjun Gokulan M


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2026 in Micromachines
Verified
Journal Article
Open access
PDF file
AMArjun Gokulan M
Arjun Gokulan M
SSSreejaa B S
Sreejaa B S
MKMohana Priya Kandan
Mohana Priya Kandan
NJNARAYANAN J
NARAYANAN J
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
Dignesh KhuntDignesh Khunt
Dignesh Khunt
Background: A transdermal drug delivery system has significant benefits over conventional routes; however, its effectiveness is limited by the barrier properties of the stratum corneum. Dissolving microneedles (DMNs) have emerged as a minimally invasive strategy to enhance drug permeation while improving patient compliance. The integration of advanced fabrication techniques such as 3D printing enables precise control over microneedle geometry and reproducibility. Objective: This study aimed to fabricate and characterize pregabalin-loaded PVA/PVP dissolving microneedle arrays using a 3D-printing-assisted mold fabrication approach for efficient transdermal drug delivery. Methods: Microneedle master molds were fabricated using 3D printing, followed by replication using polydimethylsiloxane (PDMS) to obtain negative molds. Pregabalin-loaded bilayer microneedles were prepared using a micromolding technique with PVA/PVP polymers. The formulation was evaluated through rheological analysis, scanning electron microscopy (SEM), mechanical strength testing, insertion studies, swelling behavior, drug loading efficiency, Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X-ray diffraction (XRD), and in vitro drug release studies. Results: The fabricated microneedles exhibited uniform geometry with sharp tips and no structural defects. Rheological analysis confirmed shear-thinning behavior suitable for mold filling. The microneedles demonstrated adequate mechanical strength (~3.3 N/needle) and efficient insertion into the parafilm model. Drug loading efficiency was high (92.4%), indicating effective encapsulation. FTIR analysis confirmed compatibility between drug and polymers, while DSC and XRD results indicated partial amorphization of pregabalin within the polymer matrix. The formulation showed a biphasic drug release profile with an initial burst followed by sustained release, achieving ~96.8% cumulative release over 24 h. Conclusions: The study successfully demonstrates a robust and reproducible 3D-printing-assisted approach for fabricating pregabalin-loaded dissolving microneedles. The developed system exhibited desirable mechanical, physicochemical, and drug release properties, highlighting its potential as an effective transdermal drug delivery platform.

26 August 2026 in Micromachines
Verified
Journal Article
Open access
PDF file
AMArjun Gokulan M
Arjun Gokulan M
NJNARAYANAN J
NARAYANAN J
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
KPKaran Prajapati
Karan Prajapati
SPSuhaskumar Patel
Suhaskumar Patel
Dissolving microneedles offers a minimally invasive approach for transdermal drug delivery by facilitating drug transport across the stratum corneum while overcoming several limitations associated with conventional routes of administration. Benzhydroxamic acid has demonstrated biochemical and computational evidence associated with inflammatory and pain-related pathways; however, its incorporation into a dissolving microneedle platform has not been extensively explored.This study aimed to fabricate and characterize benzhydroxamic acid-loaded dissolving microneedles using a 3D-printing-assisted mold fabrication approach for transdermal drug delivery. A stereolithography-based 3D-printed master mold was used to prepare a reverse polydimethylsiloxane mold. Benzhydroxamic acid-loaded dissolving microneedles were fabricated using a PVA/PVP polymeric matrix and evaluated for their physicochemical, mechanical, insertional, and drug-delivery characteristics. The developed microneedles exhibited shear-thinning behavior, uniform morphology, and satisfactory mechanical properties, with a compression force of 3.5 ± 0.01 N/needle and tensile strength of 3.84 ± 0.21 MPa. The formulation demonstrated a drug-loading efficiency of 94.6 ± 0.35% and effective insertion into the Parafilm® M skin-simulant model. In vitro drug release reached 97.24% over 24 h, while ex vivo skin permeation reached 94.83% over 24 h. FTIR and XRD analyses indicated successful incorporation of benzhydroxamic acid into the PVA/PVP matrix without major evidence of drug–polymer incompatibility. The findings demonstrate the feasibility of incorporating benzhydroxamic acid into a PVA/PVP dissolving microneedle platform using a 3D-printing-assisted mold fabrication approach. The developed system exhibited suitable physicochemical and mechanical characteristics, efficient drug loading, effective insertion, and satisfactory in vitro and ex vivo drug-delivery performance, supporting its potential as a transdermal drug delivery platform.

8 October 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AMArjun Gokulan M
Arjun Gokulan M
NJNARAYANAN J
NARAYANAN J
VKVivekanand Ankush Kashid
Vivekanand Ankush Kashid
RPRavish J. Patel
Ravish J. Patel
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
In the present era, modern drug delivery systems play a fundamental role in ensuring the systematic delivery of the drug into the body, reaching the desired targets. Across recent decades, the drug delivery system has evolved from simple oral and injectable formulations to interpolating with various developed techniques to fabricate innovative treatment approaches for safer, effective, and better patient compliance. Progressive techniques like nanoparticles, microparticles, liposomes, polymer-based systems, 3D printing, and biological carriers have been extensively combined with specifically targeted drug-delivery techniques across infectious, oncological, pulmonary, and neurological conditions. Microneedle transdermal patches have advanced in tandem. They have gained attention for their advancement to surpass the stratum corneum, minimal invasiveness, independent delivery, and patient compliance. This review provides a translational perspective by integrating MN materials and device engineering with drug-delivery performance, patient usability, clinical evidence, manufacturing scalability, and regulatory considerations to examine the progression of MN technologies from laboratory development toward real-world healthcare implementation. Microneedles are fabricated in different types, such as solid, coated, hollow, dissolving, and hydrogel-based, to enhance precision in dosing, better permeability, and suitability across diverse populations, and complex molecules are designed, such as proteins, peptides, hormones, vaccines, and cosmetic agents. Moreover, studies suggest MN are widely accepted by geriatric and pediatric groups, reduce anxiety, and significantly benefit individuals with trypanophobia, swallowing difficulties in the case of oral doses, and compromised venous action, in addition to breaking social inequity. MN-induced microchannels can transiently increase skin permeability and may facilitate sustained or controlled drug delivery depending on MN geometry, formulation, application conditions, skin site, and individual skin characteristics. The persistence of these microchannels and their safety profile are dependent on both device and formulation characteristics. MN is a pivotal part of the novel drug delivery system, addresses the complications arising due to conventional drug delivery, and proves to focus on the improvement of pharmacokinetic parameters, patient-centric therapy, target delivery, and real-world accessibility. Further transformation in the enhancement of MN technology can lead to clinically promising drug delivery systems for the management of long-term treatment and boost next-generation therapies.